PULMONARY DELIVERY OF 1a,25-DIHYDROXYVITAMIN D3 AND CO-ADMINISTRATION OF PARATHYROID HORMONE OR CALCITONIN

摘要

Pharmaceutical pulmonary compositions, methods of delivery to the lungs of a human and methods of treatment thereof. Pharmaceutical formulations including 1a,25-dihydroxyvitamin D₃, an alcohol such as ethanol, and a polyol such as propylene glycol. Another pharmaceutical pulmonary formulation includes 1a,25-dihydroxyvitamin D₃ and dry bulking powder, which is used in a dry powder inhaler. Another pharmaceutical formulation includes 1a,25-dihydroxyvitamin D₃ and an aerosol propellant, which is used in a metered dose inhaler. The pharmaceutical pulmonary formulations may include a second active pharmaceutical ingredient such as calcitonin or a N-terminal peptide fragment of parathyroid hormone consisting of the first (34) to (38) amino acids of SEQ ID No. 1. Pulmonary delivery of the formulations efficaciously increase serum calcium levels in mammals, manage hypocalcemia, treat calcium metabolic disorder and reduce elevated parathyroid hormone levels.